[go: up one dir, main page]

MX2018000179A - Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida. - Google Patents

Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Info

Publication number
MX2018000179A
MX2018000179A MX2018000179A MX2018000179A MX2018000179A MX 2018000179 A MX2018000179 A MX 2018000179A MX 2018000179 A MX2018000179 A MX 2018000179A MX 2018000179 A MX2018000179 A MX 2018000179A MX 2018000179 A MX2018000179 A MX 2018000179A
Authority
MX
Mexico
Prior art keywords
solid forms
imidazo
amino
pirazin
pirrolidin
Prior art date
Application number
MX2018000179A
Other languages
English (en)
Other versions
MX378495B (es
Inventor
Blatter Fritz
Evarts Jerry
Barf Tjeerd
Ingallinera Tim
Aret Edwin
Krejsa Cecile
Original Assignee
Acerta Pharma Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018000179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma Bv filed Critical Acerta Pharma Bv
Publication of MX2018000179A publication Critical patent/MX2018000179A/es
Publication of MX378495B publication Critical patent/MX378495B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)

Abstract

En algunas modalidades, la invención se refiere a formas sólidas cristalinas, incluyendo polimorfos, hidratos y formas de sal, de (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pi razin-1-il)-N-(piridin-2-il)benzamida. En algunas modalidades, la invención también se refiere a composiciones farmacéuticas que contienen las formas sólidas cristalinas, y a métodos para tratar afecciones o trastornos administrando a un sujeto una composición farmacéutica que incluye las formas, incluyendo composiciones farmacéuticas y métodos para superar los efectos de los agentes reductores de ácido. Fórmula (I) ver (Fórmula).
MX2018000179A 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida. MX378495B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28
PCT/IB2016/053988 WO2017002095A1 (en) 2015-07-02 2016-07-01 Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Publications (2)

Publication Number Publication Date
MX2018000179A true MX2018000179A (es) 2018-06-27
MX378495B MX378495B (es) 2025-03-11

Family

ID=56363881

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018000179A MX378495B (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benzamida.
MX2020014163A MX2020014163A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020014163A MX2020014163A (es) 2015-07-02 2016-07-01 Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo [1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.

Country Status (29)

Country Link
US (7) US9796721B2 (es)
EP (4) EP3317281B1 (es)
JP (3) JP6829215B2 (es)
KR (2) KR102688052B1 (es)
CN (2) CN113480542B (es)
AU (3) AU2016286548B2 (es)
CA (1) CA2991096A1 (es)
CL (1) CL2017003445A1 (es)
CY (3) CY1124519T1 (es)
DK (3) DK3613745T3 (es)
ES (3) ES2895802T3 (es)
FI (2) FI3954690T3 (es)
HR (3) HRP20211511T1 (es)
HU (3) HUE056008T2 (es)
IL (3) IL293821A (es)
LT (4) LT3317281T (es)
MA (1) MA50817B1 (es)
MD (1) MD3317281T2 (es)
MX (2) MX378495B (es)
MY (1) MY193514A (es)
PL (3) PL3317281T3 (es)
PT (3) PT3317281T (es)
RS (3) RS60411B1 (es)
RU (1) RU2018103913A (es)
SG (1) SG10201913796UA (es)
SI (3) SI3954690T1 (es)
SM (3) SMT202000304T1 (es)
WO (1) WO2017002095A1 (es)
ZA (2) ZA201800329B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3179991T (pt) * 2014-08-11 2021-11-26 Acerta Pharma Bv Combinações terapêuticas de um inibidor de btk e um inibidor de bcl-2
WO2017002095A1 (en) 2015-07-02 2017-01-05 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
HUE064978T2 (hu) 2016-06-29 2024-04-28 Tesaro Inc A petefészekrák kezelésének módszerei
CN113416194A (zh) * 2016-10-05 2021-09-21 杭州领业医药科技有限公司 Acp-196的晶型及其制备方法和药物组合物
WO2018115965A1 (en) * 2016-12-23 2018-06-28 Acerta Pharma Bv Solid forms of imidazopyrazine compounds
CN110312723B (zh) * 2017-02-20 2022-02-11 杭州领业医药科技有限公司 Acp-196盐的晶型、其制备方法、药物组合物和用途
AU2018246213A1 (en) * 2017-03-27 2019-11-07 Tesaro, Inc. Niraparib formulations
CN110944638A (zh) 2017-03-27 2020-03-31 特沙诺有限公司 尼拉帕尼组合物
US10717740B2 (en) 2017-06-13 2020-07-21 Dr. Reddy's Laboratories Limited. Solid forms of acalabrutinib and process for preparation thereof
WO2019041026A1 (en) * 2017-08-29 2019-03-07 Apotex Inc. NEW CRYSTALLINE FORMS OF ACALABRUTINIB
JP7269227B2 (ja) 2017-09-26 2023-05-08 テサロ， インコーポレイテッド ニラパリブ処方物
WO2019105359A1 (zh) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Acalabrutinib的晶型及其制备方法和用途
EP3736273A4 (en) 2018-01-05 2021-02-24 Crystal Pharmaceutical (Suzhou) Co., Ltd. NEW ACALABRUTINIB CRYSTAL FORM AND THE MANUFACTURING METHOD AND USE OF IT
WO2019159097A1 (en) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Crystalline polymorphic forms of acalabrutinib
WO2019205812A1 (zh) * 2018-04-26 2019-10-31 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
EP3587421A1 (en) 2018-06-29 2020-01-01 Sandoz AG Crystalline forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
JP7439095B2 (ja) 2018-08-29 2024-02-27 アセルタ・ファーマ・ベスローテン・フェンノートシャップ ４－｛８－アミノ－３－［（２Ｓ）－１－（ブタ－２－イノイル）－ピロリジン－２－イル］イミダゾ［１，５－ａ］－ピラジン－１－イル｝Ｎ－（ピリジン－２－イル）－ベンズアミドの調製のためのプロセス
WO2020053795A2 (en) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Process for the preparation of acalabrutinib and its intermediates
EP3830091A1 (en) * 2018-09-25 2021-06-09 Cipla Limited Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor
US20220153744A1 (en) 2019-03-27 2022-05-19 Assia Chemical Industries Ltd. Solid state forms of acalabrutinib
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
US12534467B2 (en) 2019-12-02 2026-01-27 Natco Pharma Limited Process for the preparation of Acalabrutinib
WO2021135346A1 (zh) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Acalabrutinib的新晶型及其制备方法和用途
WO2021239893A1 (en) 2020-05-29 2021-12-02 Bend Research, Inc. Amorphous solid dispersion of acalabrutinib
TWI889851B (zh) * 2020-06-19 2025-07-11 荷蘭商艾森塔製藥公司 阿卡拉布替尼馬來酸鹽劑型
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
US20240315978A1 (en) * 2021-01-13 2024-09-26 Natco Pharma Limited Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (en) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions and methods for treating lymphomas with a cdk7 inhibitor in combination with a btk inhibitor
WO2023205279A1 (en) * 2022-04-19 2023-10-26 The Johns Hopkins University Improved raman spectroscopy with the addition of aromatic compounds
AU2024218100A1 (en) * 2023-02-09 2025-08-14 Apotex Inc Crystalline forms of acalabrutinib maleate
WO2025125383A1 (en) 2023-12-11 2025-06-19 Synthon B.V. Crystalline forms of acalabrutinib hydrogen maleate

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
DE60037455T2 (de) 1999-09-17 2008-11-27 Abbott Gmbh & Co. Kg Kinaseinhibitoren als arzneimittel
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
WO2005037836A2 (en) 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
CN102924458B (zh) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
SI1931346T1 (sl) 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
CN101316845A (zh) 2005-11-17 2008-12-03 Osi医药有限公司 稠合双环mTOR抑制剂
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
WO2009076170A2 (en) 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2424368B1 (en) 2009-04-29 2014-12-31 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
EP2534151B1 (en) 2010-02-08 2018-11-14 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
ES2592152T3 (es) 2010-05-31 2016-11-28 Ono Pharmaceutical Co., Ltd. Derivado de purinona como inhibidor de Btk quinasa
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
US9580427B2 (en) 2011-05-17 2017-02-28 The Regents Of The University Of California Kinase inhibitors
WO2013003629A2 (en) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Methods and compositions for inhibition of bone resorption
CA2841080A1 (en) 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
EP2734523A1 (en) 2011-07-19 2014-05-28 Merck Sharp & Dohme B.V. 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors
HRP20190135T1 (hr) * 2011-07-19 2019-03-22 Merck Sharp & Dohme B.V. 4-imidazopiridazin-1-yl-benzamidi i 4-imidazotriazin-1-yl-benzamidi kao inhibitori btk
IL317457A (en) 2011-10-19 2025-02-01 Pharmacyclics Llc Use of Bruton's tyrosine kinase inhibitors
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP2855460B1 (en) * 2012-05-23 2017-11-08 Nerviano Medical Sciences S.r.l. Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
TW201441234A (zh) 2013-01-23 2014-11-01 Merck Sharp & Dohme Ｂｔｋ抑制劑
JP2016512549A (ja) 2013-03-14 2016-04-28 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
WO2014143807A2 (en) 2013-03-15 2014-09-18 Stromatt Scott Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
MX369503B (es) 2013-04-08 2019-11-11 Pharmacyclics Llc Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas.
UA119537C2 (uk) 2013-04-08 2019-07-10 Байєр Фарма Акцієнгезелльшафт ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ ДЛЯ ЛІКУВАННЯ ЛІМФОМ
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
AU2014358868A1 (en) 2013-12-05 2016-06-09 Acerta Pharma B.V. Therapeutic combination of a PI3K inhibitor and a BTK inhibitor
US9556150B2 (en) 2013-12-13 2017-01-31 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
WO2017002095A1 (en) 2015-07-02 2017-01-05 Acerta Pharma B.V. Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Also Published As

Publication number Publication date
SI3613745T1 (sl) 2021-12-31
CN113480542A (zh) 2021-10-08
CY1124815T1 (el) 2022-11-25
SMT202300165T1 (it) 2023-07-20
FI4209493T3 (fi) 2026-01-19
SI3317281T1 (sl) 2020-08-31
US20170029428A1 (en) 2017-02-02
CN113480542B (zh) 2025-07-25
CN108349978B (zh) 2021-07-23
EP3317281B1 (en) 2020-04-22
HRP20230417T1 (hr) 2023-07-07
EP3954690B1 (en) 2023-04-05
AU2022291635B2 (en) 2024-06-27
PT3317281T (pt) 2020-06-18
MY193514A (en) 2022-10-17
KR20180048593A (ko) 2018-05-10
MX2020014163A (es) 2022-09-29
HUE049989T2 (hu) 2020-11-30
DK3613745T3 (da) 2021-10-18
US10167291B2 (en) 2019-01-01
ZA202000300B (en) 2022-03-30
FI3954690T3 (fi) 2023-05-31
IL256633B (en) 2020-05-31
IL293821A (en) 2022-08-01
EP3613745A1 (en) 2020-02-26
HK1250511A1 (en) 2018-12-21
PT3954690T (pt) 2023-06-06
PL3613745T3 (pl) 2022-01-31
US20200255437A1 (en) 2020-08-13
DK3954690T3 (da) 2023-06-06
AU2016286548B2 (en) 2020-12-10
US20240199622A1 (en) 2024-06-20
ES2946489T3 (es) 2023-07-19
JP7091494B2 (ja) 2022-06-27
RS64195B1 (sr) 2023-06-30
LT4209493T (lt) 2026-01-26
LT3317281T (lt) 2020-07-27
RU2018103913A (ru) 2019-08-02
ZA201800329B (en) 2022-04-28
AU2022291635A1 (en) 2023-02-02
US20190337949A1 (en) 2019-11-07
CN108349978A (zh) 2018-07-31
HRP20200934T1 (hr) 2020-09-18
EP4209493A1 (en) 2023-07-12
RU2018103913A3 (es) 2019-12-31
US20220177476A1 (en) 2022-06-09
LT3613745T (lt) 2021-10-11
US10640509B2 (en) 2020-05-05
SMT202100597T1 (it) 2021-11-12
JP6829215B2 (ja) 2021-02-10
EP3613745B1 (en) 2021-09-01
JP2021073235A (ja) 2021-05-13
WO2017002095A1 (en) 2017-01-05
US20220348582A1 (en) 2022-11-03
HUE062258T2 (hu) 2023-10-28
JP2022120156A (ja) 2022-08-17
MX378495B (es) 2025-03-11
CY1124519T1 (el) 2022-03-24
RS62455B1 (sr) 2021-11-30
SI3954690T1 (sl) 2023-07-31
MA50817A (fr) 2021-04-21
LT3954690T (lt) 2023-05-25
CL2017003445A1 (es) 2018-05-11
AU2020277123B2 (en) 2022-09-29
DK3317281T3 (da) 2020-06-15
MD3317281T2 (ro) 2020-07-31
KR102688052B1 (ko) 2024-07-25
SG10201913796UA (en) 2020-03-30
AU2016286548A1 (en) 2018-02-01
EP3317281A1 (en) 2018-05-09
JP2018522877A (ja) 2018-08-16
EP3954690A1 (en) 2022-02-16
IL274066A (en) 2020-06-30
RS60411B1 (sr) 2020-07-31
SMT202000304T1 (it) 2020-07-08
US9796721B2 (en) 2017-10-24
IL274066B (en) 2022-07-01
HUE056008T2 (hu) 2022-01-28
EP4209493B1 (en) 2025-11-12
CY1126103T1 (el) 2023-11-15
PT3613745T (pt) 2021-10-14
ES2895802T3 (es) 2022-02-22
PL3317281T3 (pl) 2020-11-02
US11059829B2 (en) 2021-07-13
IL256633A (en) 2018-02-28
PL3954690T3 (pl) 2023-08-14
MA50817B1 (fr) 2021-10-29
US11820777B2 (en) 2023-11-21
HRP20211511T1 (hr) 2021-12-24
ES2797987T3 (es) 2020-12-04
CA2991096A1 (en) 2017-01-05
US20180208596A1 (en) 2018-07-26
KR20240115937A (ko) 2024-07-26
AU2020277123A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
MX2018000179A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
NZ708593A (en) Novel pyrazole derivative
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
EA201500923A1 (ru) Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2019005009A (es) 1,2,4-triazolonas 2,4,5-trisustituidas.
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
MX2015009602A (es) Piridona amidas como moduladores de canales de sodio.
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
BR112016017996A2 (pt) 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso
MX359882B (es) Amidas como moduladores de canales de sodio.
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
UY36207A (es) Inhibidores de la syk
PE20151860A1 (es) Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd
CU24330B1 (es) Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
GT201700099A (es) 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1
JOP20200024A1 (ar) مركبات ثنائي هيدروكساديازينون
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents